Abstracts Archive - Page 2105 of 2607 - ACR Meeting Abstracts

Abstract Number: 1943 • 2014 ACR/ARHP Annual Meeting
In Vivo Effects of Epratuzumab, a Monoclonal Antibody Targeting Human CD22, on B Cell Function in Human CD22 Knock-in (Huki) Mice
Carolin Brandl*¹, Lamia Özgör*¹, Miriam Wöhner^1,2, Anthony Shock³ and Lars Nitschke¹, ¹Division of Genetics, University of Erlangen, Erlangen, Germany, ²Research Institute of Molecular Pathology, Vienna, Austria, ³UCB Pharma, Slough, United Kingdom
Background/Purpose Epratuzumab is a humanized monoclonal antibody that targets the B cell-specific protein CD22 currently in Phase 3 clinical trials in patients (pts) with systemic…
Abstract Number: 1942 • 2014 ACR/ARHP Annual Meeting
Regulation of the Responses of Human B Cell Subsets to Innate Immune Signals By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Natalia V. Giltiay¹, Geraldine L. Shu², Anthony Shock³ and Edward A. Clark⁴, ¹Department of Immunology, Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³UCB Pharma, Slough, United Kingdom, ⁴Department of Immunology and Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose The B cell-associated receptor, CD22, functions to regulate adhesion and signaling through both the B cell receptor (BCR) and Toll-like receptors (TLRs) expressed in…
Abstract Number: 1941 • 2014 ACR/ARHP Annual Meeting
Neuropsychiatric Lupus Is Substantially Unaffected By B-Cell Deficiency
Jing Wen¹, Ariel Stock², Haowei Wang³, Mark Shlomchik³, Maria Gulinello² and Chaim Putterman⁴, ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric lupus (NPSLE) is one of the earliest clinical manifestations in human lupus. However, its mechanisms are not fully understood. In lupus, a compromised…
Abstract Number: 1940 • 2014 ACR/ARHP Annual Meeting
A Novel Murine Model of B Cell-Mediated Glomerular Injury Is Mediated By Cytokines
Alfred Kim¹, Shreeram Akilesh², Ania Koziell³, Sanjay Jain⁴, Jeffrey Hodgin⁵, Mark Miller⁶, Jeffrey Miner⁴ and Andrey Shaw⁷, ¹IM/Div of Rheumatology, Washington Univ School of Med, St. Louis, MO, ²Pathology & Immunolog, Washington University School of Medicine, Saint Louis, MO, ³Experimental Immunobiology, King's College, London, United Kingdom, ⁴Renal Division, Washington University School of Medicine, Saint Louis, MO, ⁵Nephrology, University of Michigan, Ann Arbor, MI, ⁶Infectious Diseases, Washington University School of Medicine, Saint Louis, MO, ⁷Pathology & Immunology/HHMI, Washington University School of Medicine, Saint Louis, MO
Background/Purpose Lupus nephritis (LN) remains the leading cause of mortality for SLE patients, and is associated with proteinuria and foot process effacement. Podocyte foot process effacement…
Abstract Number: 1939 • 2014 ACR/ARHP Annual Meeting
Development of Cell–Based Enzyme–Linked Immunosorbent Assay for the Quantification of Anti–M–type phospholipase–a–receptor Antibodies and Its Clinical Usefulness in Patients with Membranous Nephropathy
Yasuhiro Katsumata¹, Yuko Okamoto¹, Takahito Moriyama², Manabu Kawamoto¹, Hirotaka Kaneko¹, Yasushi Kawaguchi¹, Takahisa Gono¹, Masanori Hanaoka¹, Tomoaki Higuchi¹, Hidenaga Kawasumi¹, Keiko Uchida², Kosaku Nitta² and Hisashi Yamanaka³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose : Better risk prediction is needed to identify patients who will benefit from immunosuppressive therapy with idiopathic membranous nephropathy (MN) due to the variable…
Abstract Number: 1938 • 2014 ACR/ARHP Annual Meeting
Effects of Mesenchymal Stem Cells on Human B Cell Proliferation
Erin Collins¹, Maosong Qi² and Gary S. Gilkeson³, ¹Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ²Medicine/ Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Human mesenchymal stem cells (MSC) are progenitor cells that have immunomodulatory properties. MSCs have been used to treat a variety of autoimmune diseases, including…
Abstract Number: 1937 • 2014 ACR/ARHP Annual Meeting
Model Examining Factors Related to Physicians’ Ratings of Disease Activity in Patients with RA
Julia R. Ayeroff¹, Sarah R. Ormseth², David Hardy³, Michael R. Irwin², Michael H. Weisman⁴ and Perry M. Nicassio², ¹Postbaccalaureate Premedical Program, University of Southern California, Los Angeles, CA, ²Cousins Center for PNI, University of California, Los Angeles, Los Angeles, CA, ³Psychology, Loyola Marymount University, Los Angeles, CA, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: The purpose of this study was to examine a multidimensional, integrated model describing the interrelations among rheumatoid arthritis (RA) objective disease activity, patient-rated disease…
Abstract Number: 1936 • 2014 ACR/ARHP Annual Meeting
Ageism, Fear, and Competing Co-Morbidities – Why Older Patients May Not Seek Care for Restricting Back Pain: A Qualitative Study
Una Makris^1,2, Robin Higashi³, Emily Marks³, Liana Fraenkel⁴, Joanna Sale⁵ and CM Reid⁶, ¹Rheumatology, UT Southwestern Medical Center, Dallas, UT, ²Rheumatology, Dallas VA Medical Ctr, Dallas, TX, ³Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, ⁴Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, ⁵Healthy Policy, Management, and Evaluation; Mobility Program Clinical Research Unit, University of Toronto, St. Michael's Hospital, Toronto, ON, Canada, ⁶Geriatrics, Weill Cornell Medical College, New York City, NY
Background/Purpose: Back pain is highly prevalent among older adults and often undertreated. The reasons for this gap in care are poorly understood, especially in older…
Abstract Number: 1935 • 2014 ACR/ARHP Annual Meeting
Racial Disparities in Attitude Towards Treatment in Young Women
Raluca Cozmuta¹, Sonal Bhalla² and Liana Fraenkel³, ¹Rheumatology, Yale University School of Medicine, New Haven, CT, ²Yale University, New Haven, CT, ³Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT
Background/Purpose: Previous research has found that young minority women tend to be more risk averse compared to their Caucasian counterparts. The reasons underlying these differences,…
Abstract Number: 1908 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes in the Tofacitinib RA Safety Database through April 2014
A. Marren¹, Y. Chen¹, D. Frazier² and J. Geier³, ¹Pfizer Inc, Collegeville, PA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Its effect in pregnant women is of interest, as tofacitinib…
Abstract Number: 1923 • 2014 ACR/ARHP Annual Meeting
Vitamin D Restores Lupus Myeloid Angiogenic Cell Function Via Down-Regulation of IP-10/CXCL-10
John A. Reynolds¹, David W. Ray², Yvonne Alexander³ and Ian N. Bruce⁴, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, Manchester, United Kingdom, ²Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom, ³Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose Endothelial repair is important for the maintenance of vascular integrity and is impaired in patients with SLE. Myeloid angiogenic cells (MACs) contribute to endothelial…
Abstract Number: 1922 • 2014 ACR/ARHP Annual Meeting
Hydroxylchloroquine Use Is Associated with Decreased Soluble TNF Receptor Levels in SLE Patient Samples
Rufei Lu^1,2, Adam Przebinda³, Melissa E. Munroe⁴, Joel M. Guthridge¹, Joan T. Merrill⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disorder with a waxing and waning clinical course. Hydroxychloroquine (HCQ) is a well-tolerated and effective…
Abstract Number: 1921 • 2014 ACR/ARHP Annual Meeting
The Deposition of Complement C4d Split Product on Platelets and Erythrocytes Correlate with Disease Activity and Improvement in Systemic Lupus Erythematosus
Joan T. Merrill¹, Aikaterini Thanou², Stan Kamp¹, John Conklin³, Derren Barken⁴ and Thierry Dervieux⁵, ¹Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁴Exagen Diagnostics, Inc., Vista, CA, ⁵rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: We sought to evaluate the usefulness of cell bound complement activation products (C4d deposition on erythrocytes [EC4d] and platelets [PC4d]) in the monitoring of…
Abstract Number: 1920 • 2014 ACR/ARHP Annual Meeting
Predicting SLE Disease Activity in the Next Year Based on Measures of Four Gene Transcripts and Two Proteins
Laurence S Magder¹, Eric Zollars², Jadwiga Bienkowska³, Chris Stebbins⁴, Carrie Wager⁵, Linda Burkly⁶, Nicolas Wisniacki⁷, Ann Ranger⁸ and Michelle Petri⁹, ¹Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Translational Medicine, Biogen Idec, Cambridge, MA, ⁵Biostatistics, Biogen Idec, Cambridge, MA, ⁶Biogen Idec, Cambridge, MA, ⁷Formerly with Biogen Idec, Cambridge, MA, ⁸14 Cambridge Center, Biogen Idec, Cambridge, MA, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose Multiple gene transcripts and proteins in blood or urine have been observed to correlate with disease activity in SLE. However some observed associations might…
Abstract Number: 1919 • 2014 ACR/ARHP Annual Meeting
HLA-B27 Expression Shapes the Intestinal Microbiota
Mark Asquith¹, Phoebe Lin², Tejpal Gill³, Justine Debelius⁴, Patrick Stauffer⁵, Sean Davin⁵, Gail Ackermann⁴, Robert A. Colbert³, Rob Knight⁴ and James Rosenbaum^1,6, ¹Division of Rheumatology, Oregon Health and Science University, Portland, OR, ²Casey Eye Institute, Oregon Health and Science University, Portland, OR, ³NIAMS/NIH, Bethesda, MD, ⁴University of Colorado Boulder, Boulder, CO, ⁵Oregon Health and Science University, Portland, OR, ⁶Dever's Eye Institute, Legacy Hospital, Portland, OR
Background/Purpose The intestinal microbiota plays a central role in both health and disease. Beyond shaping local immune responses in the gut, it is increasingly clear…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].